SYK and retinoblastoma: BEZ235 systemic toxicity could also potentially be minimized by delivering it as localized therapy directly to the eye, as has been demonstrated with other small molecule inhibitors such as Mdm2 or Syk of other signaling pathways activated in retinoblastoma [2, 7].